New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2013
09:24 EDTSQNM, AETSequenom could benefit meaningfully from Aetna decision, says Oppenheimer
After Aetna (AET) recommended measuring cell-free fetal nucleic acids when testing for Down's syndrome in at-risk women, Oppenheimer thinks the recommendation suggests that Aetna is likely to pick up coverage of Sequenom's MaterniT21. The firm reiterates an Outperform rating on Sequenom.
News For SQNM;AET From The Last 14 Days
Check below for free stories on SQNM;AET the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 24, 2014
21:54 EDTSQNMPiper Jaffray to hold a bus tour
Subscribe for More Information
August 19, 2014
11:32 EDTSQNMLabCorp prenatal test a negative for Sequenom, says Maxim
Maxim views LabCorp's (LH) announcement today that it will begin offering the informaSeq prenatal test as a long-term negative for Sequenom (SQNM) due to increased competition. The news is also negative for Illumina (ILMN) and PerkinElmer (PKI), who both offer Non-Invasive Prenatal Tests, Maxim adds. The firm recommends buying shares of LabCorp and keeps a Buy rating on the name with a $130 price target.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use